Sana Biotechnology, Inc. (SANA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SANA Stock Price Chart Interactive Chart >
SANA Price/Volume Stats
| Current price | $8.06 | 52-week high | $44.60 |
| Prev. close | $7.95 | 52-week low | $7.66 |
| Day low | $7.66 | Volume | 2,553,563 |
| Day high | $8.10 | Avg. volume | 1,081,805 |
| 50-day MA | $15.01 | Dividend yield | N/A |
| 200-day MA | $19.60 | Market Cap | 1.52B |
Sana Biotechnology, Inc. (SANA) Company Bio
Sana Biotechnology, Inc. operates as a biotechnology company. The Company focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology replaces damaged cells and tissues and treats broad array of diseases.
Latest SANA News From Around the Web
Below are the latest news stories about Sana Biotechnology Inc that investors may wish to consider to help them evaluate SANA as an investment opportunity.
3 Biotechs That Will Soar Regardless of COVID-19In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space. |
Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological MalignanciesSana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products, |
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR ConstructLicense will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with the National Cancer Institution (NCI), an institute of the National Institutes o |
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR ConstructSEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA ), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, and Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today jointly announced that the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial ri... |
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare ConferenceSEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Tuesday, January 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of |
SANA Price Returns
| 1-mo | -47.63% |
| 3-mo | -61.14% |
| 6-mo | -50.52% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.93% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...